Semaglutide titration planner: Ozempic, Wegovy and tablet schedules by date

Semaglutide titration is slow on purpose. The labels step the dose up every 4 weeks (injections) or 30 days (tablets) to reduce gastrointestinal reactions, and every step is a date you need to know in advance: the pharmacy needs the next strength in hand and your prescriber needs to have agreed to the increase. The planner does the calendar part.

What you give it

A product, a first-dose date, and the maintenance dose your prescriber chose. That last field is blank on purpose. The tool then lays out each label step with its start and end date, marks the day maintenance begins, totals the milligrams across the plan, and exports every injection (or every tablet phase) as a calendar file.

You can hold any escalation step longer than the label minimum. The Wegovy label says that if a dose is not tolerated, consider delaying escalation for 4 weeks; the Ozempic label says each increase comes "after at least 4 weeks" at the previous dose. Longer is allowed. Shorter is not, and the tool refuses it.

The five schedules it knows

Wegovy injection. Weeks 1 to 4 at 0.25 mg, 5 to 8 at 0.5 mg, 9 to 12 at 1 mg, 13 to 16 at 1.7 mg. Maintenance from week 17 is 2.4 mg (recommended) or 1.7 mg for weight reduction and cardiovascular risk reduction. For adults on weight reduction who tolerate 2.4 mg for at least 4 weeks and need more weight reduction, the dose may be increased to 7.2 mg (Wegovy HD, approved March 19, 2026, Drugs@FDA NDA 215256 supplement 29). The planner models 7.2 mg as 4 weeks at 2.4 mg followed by 7.2 mg.

Ozempic injection. 0.25 mg once weekly for 4 weeks, then 0.5 mg. The 0.25 mg dose is for initiation and is not intended for glycemic control. If more glycemic control is needed, 1 mg after at least 4 weeks at 0.5 mg, and 2 mg after at least 4 weeks at 1 mg. Maintenance is 0.5, 1 or 2 mg. The kidney indication (added January 28, 2025) specifies 1 mg after 4 weeks at 0.5 mg.

Wegovy tablets. Days 1 to 30 at 1.5 mg, 31 to 60 at 4 mg, 61 to 90 at 9 mg, then 25 mg once daily from day 91. One tablet a day, in the morning, on an empty stomach, with up to 4 ounces of water, then nothing by mouth for 30 minutes.

Rybelsus. 3 mg once daily for 30 days (not effective for glycemic control on its own), then 7 mg. 14 mg if additional glycemic control is needed after at least 30 days at 7 mg.

Ozempic tablets. 1.5 mg once daily for 30 days, then 4 mg. 9 mg if additional glycemic control is needed after at least 30 days at 4 mg. This is the newer oral formulation approved for type 2 diabetes; see the tablets guide for how it relates to Rybelsus.

Reading the plan

The table shows each phase with its dates. The maintenance row is shaded. For injections, a collapsed list shows every dose date and weekday; step-change rows are shaded there too. Those are the dates to confirm two things: that the next pen strength or vial is in hand, and that your prescriber has actually said yes to the increase. A shaded row is a reminder to ask, not permission.

The total-milligrams figure is useful for supply planning. Twenty weeks of the Wegovy plan to 2.4 mg uses 23.4 mg of semaglutide (4 weeks each at 0.25, 0.5, 1, 1.7 and 2.4 mg). If you are on a vial product, the units converter tells you how many doses a vial holds at each step.

What the planner will not do

It does not reschedule after a missed dose; the missed-dose helper applies those rules. It does not tell you whether to step up. It does not model the Wegovy label's temporary step-down from 2.4 mg to 1.7 mg for MASH patients who do not tolerate the higher dose, or Ozempic's decision points about glycemic control, because both are clinical judgments. And it knows nothing about compounded semaglutide beyond the calendar: compounded products are not FDA approved, have no label, and take whatever schedule your prescriber wrote. For a fully custom schedule, the injection schedule generator on the FormBlends Calculators site accepts any steps.

If you are comparing products before a prescriber visit, the Ozempic vs Wegovy comparison lays the two injection schedules side by side, and FormBlends describes what its own compounded semaglutide program involves.